MME and COVID-19: Therefore, we think that in a “multi-targeted” therapeutic strategy for COVID-19, where the inflammatory burden is antagonized by specific anti-inflammatory drugs such as corticosteroids (dexamethasone) and tocilizumab, NEP antagonism becomes relevant for prevention of organ injury (Figure 3).